Gilead’s Lenacapavir is set to revolutionise HIV prevention efforts, aiming to protect two million people across affected nations.
Gilead’s Lenacapavir to Reach High-Burden Nations ‘At Cost’
Original Article by Gram Slattery | Reuters | 5 September 2025
More Articles
Dis-Chem Insurance Branding Non-Compliant says CMS
Dis-Chem health insurance branding issues raise enforcement risk for Centriq’s MyHealth products and potential disruption for policyholders.
National Health Insurance Negotiations: SAMA Seeks NHI Talks
National Health Insurance Negotiations: SAMA meets Motsoaledi after Godongwana urges NHI litigants to seek a settlement.
NHI Truce Talks: Godongwana Pushes Settlement On NHI
NHI truce talks could end court battles and shift focus to workable reforms for universal health coverage.